Summary
Regeneron Pharmaceuticals, Inc. (REGN) announced a significant addition to its Board of Directors with the appointment of Ms. Christine A. Poon, effective November 12, 2010. Ms. Poon brings extensive experience in the pharmaceutical sector, having previously served as Vice Chairman of the Board and Worldwide Chairman of the Johnson & Johnson Pharmaceuticals Group. Her expertise is expected to be valuable as she joins the Board's Compensation Committee and Corporate Governance Committee. This appointment is accompanied by a standard director compensation package, including annual cash retainers and meeting fees, as well as an initial stock option grant of 25,000 shares and future annual grants. The inclusion of a seasoned executive like Ms. Poon signals a continued focus on strategic governance and oversight, which is crucial for a company in the competitive biotechnology and pharmaceutical landscape.
Key Highlights
- 1Regeneron Pharmaceuticals appointed Ms. Christine A. Poon as a new director, effective November 12, 2010.
- 2Ms. Poon has a strong background in the pharmaceutical industry, previously holding key leadership roles at Johnson & Johnson.
- 3She will serve on the Board’s Compensation Committee and Corporate Governance Committee, indicating a focus on executive compensation and company governance.
- 4Ms. Poon received an initial stock option grant for 25,000 shares with an exercise price of $25.45.
- 5Future annual stock option grants of 15,000 shares are planned, subject to continued service.
- 6All stock option grants vest over three years and have a ten-year expiration period.
- 7The appointment is detailed in an exhibit filed as a press release dated November 15, 2010.